{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:47:07Z","timestamp":1778629627138,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Deanship of Scientific Research at King Saud University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jchromb.2014.12.036","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T19:37:23Z","timestamp":1421264243000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A validated UPLC\u2013MS\/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma"],"prefix":"10.1016","volume":"983-984","author":[{"given":"Muzaffar","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essam","family":"Ezzeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A.","family":"Al-Rashood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiyaz","family":"Shakeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2014.12.036_bib0105","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0115","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0120","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0125","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0135","series-title":"Approved drugs: Pomalidomide","author":"US Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0140","series-title":"Imnovid (pomalidomide). Summary of product characteristics","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0145","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40265-013-0047-x","article-title":"Pomalidomide: first global approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","article-title":"Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration","volume":"71","author":"Hoffmann","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0155","series-title":"Pomalyst (pomalidomide) Prescribing Information","author":"Celgene","year":"2013"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.1463","article-title":"Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma","volume":"34","author":"Highsmith","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jpba.2014.01.001","article-title":"A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses","volume":"92","author":"Shahbazi","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0170","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpba.2013.08.036","article-title":"Sensitive liquid chromatography\/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue","volume":"88","author":"Jiang","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0175","series-title":"Guidance for Industry on Bioanalytical Method Validation","author":"Center for Drug Evaluation and Research","year":"2001"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0180","series-title":"Guideline on Bioanalytical Method Validation","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0185","first-page":"371","article-title":"UPLC: a preeminent technique in pharmaceutical analysis","volume":"69","author":"Kumar","year":"2012","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0190","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/rcm.3389","article-title":"A novel 'peak parking' strategy for ultra-performance liquid chromatography\/tandem mass spectrometric detection for enhanced performance of bioanalytical assays","volume":"22","author":"Li","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2014.12.036_bib0195","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.talanta.2005.06.035","article-title":"Advantages of application of UPLC in pharmaceutical analysis","volume":"68","author":"Novakova","year":"2006","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2014.12.036_bib0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J. Chromatogr. B"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023215000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023215000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:05:35Z","timestamp":1690848335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023215000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":20,"alternative-id":["S1570023215000252"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2014.12.036","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A validated UPLC\u2013MS\/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2014.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}